Allianz Asset Management GmbH - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.

Quarter-by-quarter ownership
Allianz Asset Management GmbH ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2022$711,000
-6.7%
12,4500.0%0.00%0.0%
Q1 2022$762,000
+16.9%
12,4500.0%0.00%
Q4 2021$652,000
+40.5%
12,4500.0%0.00%
Q3 2021$464,000
-37.7%
12,450
-31.8%
0.00%
-100.0%
Q2 2021$745,000
-28.9%
18,250
-40.9%
0.00%0.0%
Q1 2021$1,048,000
+6.7%
30,8850.0%0.00%0.0%
Q4 2020$982,000
+23.8%
30,8850.0%0.00%0.0%
Q3 2020$793,000
+74.7%
30,885
+74.9%
0.00%0.0%
Q2 2020$454,000
-17.6%
17,659
-50.7%
0.00%0.0%
Q1 2020$551,000
-43.7%
35,831
+25.6%
0.00%0.0%
Q4 2019$979,000
+248.4%
28,522
-24.1%
0.00%
Q3 2019$281,000
+8.1%
37,564
+87.6%
0.00%
Q2 2019$260,000
-76.3%
20,020
-49.3%
0.00%
-100.0%
Q1 2016$1,097,000
-87.5%
39,452
-75.8%
0.00%
-90.0%
Q4 2015$8,786,000
+14.1%
163,336
-15.0%
0.01%
+11.1%
Q3 2015$7,697,000192,2380.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2020
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders